PE20191081A1 - Nuevos receptores de celulas t y terapia inmunologica que los utiliza - Google Patents
Nuevos receptores de celulas t y terapia inmunologica que los utilizaInfo
- Publication number
- PE20191081A1 PE20191081A1 PE2019001096A PE2019001096A PE20191081A1 PE 20191081 A1 PE20191081 A1 PE 20191081A1 PE 2019001096 A PE2019001096 A PE 2019001096A PE 2019001096 A PE2019001096 A PE 2019001096A PE 20191081 A1 PE20191081 A1 PE 20191081A1
- Authority
- PE
- Peru
- Prior art keywords
- new
- cell receptors
- refers
- mentioned above
- construct
- Prior art date
Links
Classifications
-
- G01N33/575—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G01N33/5759—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
Abstract
Se refiere a una construccion de reconocimiento de antigeno contra un antigeno asociado a tumor (TAA) caracterizada porque comprende por lo menos una region determinante de complementariedad (CDR) 3 que tiene al menos 50% de identidad de secuencia con una secuencia de aminoacidos seleccionada de las SEQ ID Nos 3, 9, 15, 21, 27 y 33. Tambien se refiere a un acido nucleico que codifica para una construccion mencionada antes, una celula huesped y una composicion farmaceutica que comprenden una construccion mencionada antes, y metodos de preparacion. La presente invencion es util para el diagnostico, tratamiento y prevencion de enfermedades cancerosas que expresan TAA
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662431580P | 2016-12-08 | 2016-12-08 | |
| DE102016123859.7A DE102016123859B3 (de) | 2016-12-08 | 2016-12-08 | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| PCT/EP2017/081893 WO2018104478A1 (en) | 2016-12-08 | 2017-12-07 | Novel t cell receptors and immune therapy using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191081A1 true PE20191081A1 (es) | 2019-08-20 |
Family
ID=61167304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019001096A PE20191081A1 (es) | 2016-12-08 | 2017-12-07 | Nuevos receptores de celulas t y terapia inmunologica que los utiliza |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10527623B2 (es) |
| EP (1) | EP3551654A1 (es) |
| JP (1) | JP2020511936A (es) |
| KR (1) | KR20190086562A (es) |
| CN (1) | CN110036027A (es) |
| AU (1) | AU2017373815C1 (es) |
| BR (1) | BR112019010699A2 (es) |
| CA (1) | CA3045234A1 (es) |
| CR (1) | CR20190276A (es) |
| DE (1) | DE102016123859B3 (es) |
| MX (1) | MX2019006727A (es) |
| PE (1) | PE20191081A1 (es) |
| TW (1) | TW201828977A (es) |
| WO (1) | WO2018104478A1 (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021173560A1 (en) | 2020-02-24 | 2021-09-02 | Immatics US, Inc. | Methods for expanding t cells for the treatment of cancer and related malignancies |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| AU2019218093A1 (en) | 2018-02-09 | 2020-09-10 | Immatics US, Inc. | Methods for manufacturing T cells |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| CA3097399A1 (en) | 2018-04-19 | 2019-10-24 | The Board Of Regents, The University Of Texas System | T cell receptors with mage-b2 specificity and uses thereof |
| DE102019108125B4 (de) | 2019-03-28 | 2022-02-03 | Immatics US, Inc. | Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung |
| WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| TWI872076B (zh) | 2019-05-27 | 2025-02-11 | 美商英麥提克斯股份有限公司 | 病毒載體及其在授受性細胞療法之應用 |
| CA3142386A1 (en) | 2019-06-06 | 2020-12-10 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
| WO2021005108A1 (en) * | 2019-07-09 | 2021-01-14 | Medigene Immunotherapies Gmbh | Magea10 specific t cell receptors and their use |
| US20220260563A1 (en) * | 2019-08-01 | 2022-08-18 | The University Of Carolina At Chapel Hill | Compositions and methods for binding antibodies and inhibiting neutralizing antibodies |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| WO2021086991A1 (en) * | 2019-10-30 | 2021-05-06 | The Regents Of The University Of California | Methods of treating systemic lupus erythematosus |
| KR102488967B1 (ko) * | 2019-11-08 | 2023-01-16 | 주식회사 굳티셀 | 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체 |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| CN111574616B (zh) * | 2020-06-17 | 2021-02-02 | 深圳豪石生物科技有限公司 | 分离的t细胞受体和应用 |
| CN111624342A (zh) * | 2020-07-11 | 2020-09-04 | 成都益安博生物技术有限公司 | 一种卵巢癌的外周血tcr标志物及其检测试剂盒和应用 |
| TW202227616A (zh) | 2020-08-21 | 2022-07-16 | 美商英麥提克斯股份有限公司 | 分離ｃｄ８＋選擇ｔ細胞的方法 |
| DE102021100038A1 (de) | 2020-12-31 | 2022-06-30 | Immatics US, Inc. | Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung |
| MX2023007817A (es) | 2020-12-31 | 2023-09-13 | Immatics Us Inc | Polipéptidos de cd8, composiciones y métodos de uso de estos. |
| KR20240004937A (ko) | 2021-05-05 | 2024-01-11 | 이매틱스 바이오테크놀로지스 게엠베하 | Bma031 항원 결합 폴리펩타이드 |
| US20240358831A1 (en) | 2021-08-24 | 2024-10-31 | Immatics US, Inc. | Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange |
| US20230089392A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| EP4408468A4 (en) | 2021-09-28 | 2025-07-02 | Frontaim Biomedicines Inc | MULTIPLE FORMATS OF MOLECULAR COMPLEXES |
| EP4448108A1 (en) | 2021-11-08 | 2024-10-23 | Immatics Biotechnologies GmbH | Adoptive cell therapy combination treatment and compositions thereof |
| WO2023081461A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
| US20250009799A1 (en) * | 2021-12-21 | 2025-01-09 | Amgen Inc. | Dcaf4l2-specific t-cell receptors |
| JP2025515604A (ja) | 2022-04-28 | 2025-05-20 | イマティクス ユーエス，アイエヌシー． | ドミナントネガティブＴＧＦβ受容体ポリペプチド、ＣＤ８ポリペプチド、細胞、組成物、およびその使用方法 |
| CA3250304A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | IL-15 Bound to a Membrane, CD8 Polypeptides, Cells, Compositions and Related Methods of Use |
| WO2023212655A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| EP4519418A1 (en) | 2022-05-05 | 2025-03-12 | Immatics US, Inc. | Methods for improving t cell efficacy |
| CN115216514A (zh) * | 2022-08-01 | 2022-10-21 | 中国科学技术大学 | Vam6（Vps39）作为靶点在药物筛选、基因编辑以及疾病治疗中的应用 |
| WO2024139780A1 (zh) * | 2022-12-26 | 2024-07-04 | 上海市第一人民医院 | 靶向巨细胞病毒pp65的T细胞受体和表达其的T细胞及应用 |
| AU2024298426A1 (en) * | 2023-07-25 | 2026-01-15 | Memorial Hospital For Cancer And Allied Diseases | T cell receptors targeting tp53 hotspot mutations and uses thereof |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| US20020197266A1 (en) | 2000-02-08 | 2002-12-26 | Waldemar Debinski | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| EP2660250B1 (en) * | 2012-05-02 | 2018-11-14 | Deutsches Rheuma-Forschungszentrum Berlin | Tcr transgenic mouse model for immune disease |
| ES2925307T3 (es) | 2012-09-14 | 2022-10-14 | Us Health | Receptores de linfocitos T que reconocen MAGE-A3 restringida al MHC de clase II |
| US11203783B2 (en) * | 2013-11-21 | 2021-12-21 | Repertoire Genesis Incorporation | T cell receptor and B cell receptor repertoire analysis system, and use of same in treatment and diagnosis |
| ES2959683T3 (es) * | 2014-07-15 | 2024-02-27 | Juno Therapeutics Inc | Células manipuladas para terapia celular adoptiva |
| CN105506065A (zh) * | 2014-09-25 | 2016-04-20 | 上海人类基因组研究中心 | 肝癌基因检测方法、检测试剂盒及其应用 |
| GB201505305D0 (en) * | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| GB201520583D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
-
2016
- 2016-12-08 DE DE102016123859.7A patent/DE102016123859B3/de not_active Expired - Fee Related
-
2017
- 2017-12-07 PE PE2019001096A patent/PE20191081A1/es unknown
- 2017-12-07 MX MX2019006727A patent/MX2019006727A/es unknown
- 2017-12-07 US US15/835,095 patent/US10527623B2/en not_active Expired - Fee Related
- 2017-12-07 BR BR112019010699-5A patent/BR112019010699A2/pt not_active IP Right Cessation
- 2017-12-07 JP JP2019528908A patent/JP2020511936A/ja active Pending
- 2017-12-07 KR KR1020197019008A patent/KR20190086562A/ko not_active Abandoned
- 2017-12-07 CR CR20190276A patent/CR20190276A/es unknown
- 2017-12-07 EP EP17825768.9A patent/EP3551654A1/en not_active Withdrawn
- 2017-12-07 CN CN201780075298.4A patent/CN110036027A/zh active Pending
- 2017-12-07 CA CA3045234A patent/CA3045234A1/en not_active Abandoned
- 2017-12-07 WO PCT/EP2017/081893 patent/WO2018104478A1/en not_active Ceased
- 2017-12-07 AU AU2017373815A patent/AU2017373815C1/en not_active Ceased
- 2017-12-08 TW TW106143135A patent/TW201828977A/zh unknown
-
2018
- 2018-07-02 US US16/025,434 patent/US10725044B2/en not_active Expired - Fee Related
-
2020
- 2020-03-24 US US16/828,577 patent/US20200249233A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN110036027A (zh) | 2019-07-19 |
| WO2018104478A1 (en) | 2018-06-14 |
| KR20190086562A (ko) | 2019-07-22 |
| MX2019006727A (es) | 2019-09-09 |
| US20180164315A1 (en) | 2018-06-14 |
| US20180306789A1 (en) | 2018-10-25 |
| US20200249233A1 (en) | 2020-08-06 |
| JP2020511936A (ja) | 2020-04-23 |
| AU2017373815A1 (en) | 2019-06-27 |
| CR20190276A (es) | 2019-10-30 |
| AU2017373815C1 (en) | 2021-08-26 |
| AU2017373815B2 (en) | 2020-12-10 |
| TW201828977A (zh) | 2018-08-16 |
| CA3045234A1 (en) | 2018-06-14 |
| DE102016123859B3 (de) | 2018-03-01 |
| US10527623B2 (en) | 2020-01-07 |
| BR112019010699A2 (pt) | 2019-10-22 |
| EP3551654A1 (en) | 2019-10-16 |
| US10725044B2 (en) | 2020-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191081A1 (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza | |
| PE20191648A1 (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza | |
| CY1121348T1 (el) | Mrna θεραπεια για την θεραπευτικη αγωγη οφθαλμικων ασθενειων | |
| TR201908291T4 (tr) | Şifrelenmiş bir tümör antijeninin ekspresyonunun arttırılmasına yönelik bir histon sap-ilmiği ve bir poli(a) sekansı veya bir poliadenilasyon sinyali içeren veya bunun için kodlama yapan nükleik asit. | |
| MX395287B (es) | Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos. | |
| MX2022015821A (es) | Nuevos receptores de celulas t y usos de los mismos. | |
| CL2019003885A1 (es) | Receptores de células t novedosos, e inmunoterapia usando los mismos. | |
| PE20191152A1 (es) | Anticuerpos y polipeptidos dirigidos contra cd127 | |
| MX2021001098A (es) | Anticuerpos de un solo dominio dirigidos contra antigenos intracelulares. | |
| BR112019008010A2 (pt) | anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica | |
| EA201792573A1 (ru) | Триспецифические связанные белки и способы их применения | |
| PE20171654A1 (es) | Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer | |
| EA202090751A3 (ru) | Новый метод иммунотерапии нескольких видов опухолевых заболеваний крови, таких как острый миелоидный лейкоз (омл) | |
| MX2015013065A (es) | Proteinas f de rsv de prefusion y su uso. | |
| PE20161311A1 (es) | Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos. | |
| CY1121734T1 (el) | ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ | |
| MX2020010701A (es) | Péptidos antigénicos para la prevención y el tratamiento del cáncer. | |
| PE20161245A1 (es) | Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos | |
| PE20191786A1 (es) | Anticuerpo monoclonal para pd-l1 | |
| CL2019000722A1 (es) | Nueva vacuna contra la gripe porcina. | |
| MX2019005491A (es) | Anticuerpo que enlaza especificamente a cd66c y uso del mismo. | |
| MX2021000853A (es) | Vacunas individualizadas para el cancer. | |
| MX2017013177A (es) | Anticuerpo anti-vegfr2 humano para terapia del cancer anti-angiogenica y dirigida. | |
| AR095387A1 (es) | Proteínas específicas para el baff y para la b7rp1 y sus usos | |
| MX2013009757A (es) | Metodo de seleccion rapida para vih variantes gp-120. |